37 reports of this reaction
1.8% of all CARBOPROST TROMETHAMINE reports
#13 most reported adverse reaction
HYPERHIDROSIS is the #13 most commonly reported adverse reaction for CARBOPROST TROMETHAMINE, manufactured by Pharmacia & Upjohn Company LLC. There are 37 FDA adverse event reports linking CARBOPROST TROMETHAMINE to HYPERHIDROSIS. This represents approximately 1.8% of all 2,057 adverse event reports for this drug.
Patients taking CARBOPROST TROMETHAMINE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for CARBOPROST TROMETHAMINE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for CARBOPROST TROMETHAMINE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 37 FDA reports for CARBOPROST TROMETHAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.8% of all adverse event reports for CARBOPROST TROMETHAMINE, making it a notable side effect.
If you experience hyperhidrosis while taking CARBOPROST TROMETHAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.